Stock
Guru

What happenedOrganic clinical usage: Q2 2026 (ended 30 Jun 2026) revenue was $64.1M, +48% YoY, with global revenue cases +74% to 84,491 driven by deeper utilisation at existing sites plus ramping new accounts. US revenue +51%, and the Plaque analysis product is a fast-growing second engine ($7.8M, ~$4M above plan).

BullPer-analysis software model (FFRct + Plaque) at ~83% gross margin, case volume +74% YoY, Plaque adoption still early vs a ~60% applicability target, and FY26 guidance raised to $246-250M (~40-42% growth) on 13 Aug 2026 - a clean organic volume ramp, no M&A or milestones.

BearStill loss-making (Q2 GAAP net loss $15.7M), FFRct average selling prices are under pressure into 2027, an active CID government investigation and IP litigation are overhangs, and guidance implies only modest sequential H2 growth, so the 40-48% prints can decelerate.

NarrativeNewly public (IPO 8 Aug 2025 at $19); ~9-10 analysts, consensus Buy with ~$40-45 targets; the 13 Aug 2026 beat-and-raise was well received. Overhangs are the disclosed CID investigation and IP litigation; lockup already expired. Retail buzz modest - a niche medtech AI name, not a meme stock. Next print mid-Nov 2026.

What happenedRevenue of $21.56B (+37.7% YoY, quarter ended 31 Aug 2026) is organic, driven by AI infrastructure demand: Hyve Solutions revenue +51.7% to $3.80B with non-GAAP gross billings +117.5%, plus data-centre modernisation and enterprise AI deployments lifting both Distribution and Hyve above plan.

BullGenuine organic AI-driven demand with operating leverage - non-GAAP operating income +55% and EPS $5.68 (+58.7%) beat, Q4 guided well above consensus; analysts raised targets (Morgan Stanley $359 OW, UBS $379 Buy).

BearClassic thin-margin distributor dynamic: gross profit grew only 26.2% vs 37.7% revenue (margin compressed 61bps) as low-margin AI racks dilute mix, and the growth burned cash - operating cash flow swung to -$917M on a large AR/inventory build, which is why the stock fell ~3% on a beat-and-raise.

NarrativeRecord beat-and-raise with analysts boosting targets (UBS $379, MS $359) and CEO saying datacentre demand 'isn't cracking', yet the stock sold off ~3% on margin contraction, negative free cash flow and the working-capital build. Next catalyst fiscal Q4 2026 (ending ~30 Nov 2026).

What happenedQ2 2026 (ended 30 Jun 2026) revenue rose 23% YoY to $16.1M, beating ~$15.2M consensus; handheld product/service revenue +24% to $15.5M on organic FTIR/VipIR demand (35+ VipIR units shipped) plus NIRLab law-enforcement revenue from the 6 May 2026 acquisition. State/local public-safety is >50% of revenue.

BullPost-divestiture pure-play on handheld forensics/defence/public-safety with secular tailwinds (opioid response, border security, defence budgets); installed base +23% to 4,101 devices, ~31% recurring service revenue, FY2026 guidance raised to $68-70M (21-25% growth), $101.5M cash and no debt.

BearStill deeply loss-making (continuing-ops net loss $11.9M); the 23% blends organic ramp with the inorganic NIRLab bolt-on (closed May 2026, ~2 months in the quarter), so it isn't cleanly organic, and >50% of revenue is lumpy government budget-driven orders with comps still distorted by the 2025 bioprocessing divestiture.

NarrativeConstructive: Roth raised PT to $13 and Stifel to $12 (both Buy) on 12 Aug 2026 after the beat-and-raise, consensus Moderate Buy ~$12.83, and the stock hit a 1-year high in late Sept; short interest elevated (~13% of float) signalling real skepticism on durability. Next catalyst Q3 2026 ~early Nov 2026.

What happenedQ1 FY2027 (ended 31 Jul 2026) revenue was a record $2.03B, a genuinely-reported +30% YoY (clean Q1-vs-Q1, not a screener artifact), driven by all-flash arrays jumping 47% to $1.31B on AI/GPU storage demand plus Public Cloud +28%. Management flagged the figure is inflated by an extra 14th week, accelerated/pull-forward purchases and non-durable pricing.

BullFully organic, no acquisition; AI-era standardisation on all-flash drove 47% flash growth and management raised FY27 revenue guidance by ~$650M to an $8.1B midpoint (~17% growth), implying some of the step-up is structural. #1 all-flash share per IDC.

BearThe 30% overstates the run-rate: it includes a 14th week, pull-forward demand and temporary pricing gains management admits may not repeat; FY guidance implies H2 decelerates to ~9-10%, and the prior two quarters (+2.8%, +4.4%) show no gradual build-up. Stock fell ~9% on the print.

Narrative'AI storage breakout' narrative with aggressively raised guidance, yet shares sold off ~9% on durability fears; Street cautious (~10 buy / 15 hold), Evercore upgraded. Next catalyst Q2 FY2027 around 1 Dec 2026, guided ~$2.1B (+23% midpoint).

What happenedQ2 FY2027 (ended 31 Jul 2026) revenue was $771.8M, +30% YoY, driven by organic Atlas consumption ($565.9M, ~73% of revenue, +29%) plus a re-acceleration in Enterprise Advanced/self-managed (+36% to $181.2M). Net ARR expansion rose to 122% and a record 2,900 net new customers were added.

BullProfitable inflection (net income $40.9M vs a year-ago loss), 122% net retention, record customer adds, RPO +91%, and early AI tailwinds (Voyage AI, Vector Search outpacing company growth); FY2027 guidance raised to $2.99-3.03B.

BearThe 'acceleration' is partly optical: Atlas (~73% of revenue, the metric that matters) has been stuck at ~29% for five quarters and is guided down to ~27%, with total growth flattered by the EA line and comps; the stock fell ~13-14% on the print, PTs were cut, and CEO CJ Desai abruptly left for Meta on 28 Sep 2026.

NarrativeClassic 'beat-and-raise sells off' - estimates topped and guidance lifted, but shares dropped ~13-14% because Atlas held at ~29% rather than re-accelerating; analysts split (MS raised, Baird downgraded) though consensus stays Buy (~27-41 analysts, avg PT ~$446). Retail/AI-database buzz remains high - a caution signal. Next catalyst Q3 FY2027 on 7 Dec 2026.

What happenedThe +91% then +113% YoY jumps come from the BD Biosciences & Diagnostic Solutions combination (Reverse Morris Trust) that closed 9 Feb 2026 and now consolidates into Waters. Of Q2 2026's $1.645B revenue, $817M was the acquired business versus $828M organic - roughly half the top line is the bolt-on.

BullUnderlying organic growth was still ~9% constant-currency with every guidance line raised, and secular drivers (GLP-1 testing +40%, BACTEC instrument replacement cycle) look real as the combined company gains scale in regulated, high-volume diagnostics.

BearThe headline acceleration is pure merger math against a prior-year base with no BD revenue, not an organic inflection; it lapses once the deal anniversaries (~Q1 2027). Integration risk, FX drag and China softness add to the doubt.

NarrativeModest beat with guidance raised but a muted-to-mixed stock reaction; analysts are sceptical on the durability of acquired-business growth and FX. Next catalyst is Q3 2026 earnings on 3 Nov 2026.

What happenedQ2 2026 revenue of $32.8M (vs $6.9M a year earlier) was driven almost entirely by a one-time $24.5M Sanofi regulatory milestone for the U.S. approval of TZIELD, plus $7.3M of royalties (up from $1.3M). The +378% YoY spike is a single collaboration payment, not a product ramp.

BullReal partnered ADC/bispecific pipeline with multiple 2026-2027 readouts (MGC026 ESMO Oct 2026, lorigerlimab LINNET H1 2027) and ~$327M pro-forma cash with runway to 2028, so further milestones and a growing royalty base could keep lumpy revenue elevated.

BearThe +378% is a non-recurring milestone that reverts toward a ~$7M royalty base next quarter; the company still ran an operating loss ex-milestone and is a sub-$6 clinical-stage biotech selling off manufacturing to fund burn.

NarrativeThin coverage (~4 analysts), consensus Hold/Buy with targets ~$6-12; news flow is milestone/pipeline-driven with an FDA partial hold on lorigerlimab as an overhang. No heavy retail hype, but a low-priced small-cap biotech where single data points swing the stock.

What happenedQ1 FY27 (ended 31 Jul 2026) net sales +32.3% YoY to $112.6M on unit shipments up ~20% (vs adjusted NICS checks up only 7.7%), long-gun/MSR strength and new products at 35% of shipments led by the Model 1854 lever-action doubling - but it laps a weak prior-year quarter (net loss, ~-3.9% revenue) and the margin beat was flattered by a $2.9M one-off tariff refund.

BullShipments outran sell-through (NICS +7.7%), signalling share gains; distributor inventory fell 6.8% sequentially, and new products (Model 1854 hunting push) expand the addressable market with limited promotion. Lake Street Buy, PT raised to $16.50.

BearThe 32% is a low-comp/timing spike: management guides Q2 to only ~+10% and full-year FY27 to just +5-7%, so growth decelerates hard; firearms demand is cyclical/seasonal and the quarter included a seasonal inventory build plus a one-off tariff refund.

NarrativeThin coverage (~2 analysts); Lake Street raised PT to $16.50 (Buy), consensus skews Strong Buy ~$17.25 avg, but the Street is anchored to management's modest 5-7% full-year guide. Next print ~3 Dec 2026, guided ~+10% YoY.

What happenedThe jump to ~25% YoY growth is driven almost entirely by two December 2025 UCaaS acquisitions - FluentStream (closed 1 Dec 2025, ~$50.5M) and Phone.com (closed 26 Dec 2025, ~$22.6M) - now fully consolidated. Management said that excluding these, Q2 FY2027 (ended 31 Jul 2026) revenue grew only ~8% YoY, in line with its historical slow-growth profile.

BullQ2 FY2027 revenue was $83.2M (+25%) with subscription 91% of mix, GAAP net income up to $3.0M, non-GAAP net income +58% and adjusted EBITDA +74%; FY2027 guidance raised to $332-333.5M, suggesting the acquired UCaaS assets are margin-accretive.

BearThe headline growth is an acquisition artifact that rolls off within ~12 months; underlying organic growth is only ~8%, consistent with the historically slow (~5-8%) business, so the screener's 'inflection' is mechanical consolidation and comps decelerate sharply once the deals anniversary (from the Jan-2026 quarter).

NarrativeReported 26 Aug 2026; coverage framed it as a beat with raised FY2027 guidance and improving profitability, but explicitly attributed the top-line surge to FluentStream/Phone.com rather than organic demand. Next catalyst Q3 FY2027 (ending 31 Oct 2026), late Nov/early Dec 2026, which will start to show the deceleration.